Avstera Therapeutics Corp.

Avstera Therapeutics is an oncology-focused biotechnology company located in the Philadelphia area. They are dedicated to developing novel therapies to address the significant unmet need of advanced cancer patients with limited or no treatment options. Their focus is on foundational tumor biology science, and they leverage cutting-edge approaches to tackle key immunological challenges seen in the tumor microenvironment. Avstera has a pipeline of three preclinical stage therapies: a highly selective HDAC6i, an autologous ex-vivo HDAC6i activated macrophage-based cell therapy, and a mRNA TEM1 cancer vaccine.

Avstera collaborates with top cancer researchers at Georgetown University and the University of Pennsylvania. They have secured funding through a seed round and received Orphan Drug Designation from the FDA for their lead HDAC6i, AVS100, for the treatment of advanced stage melanoma. Avstera is committed to developing innovative therapies that improve the lives of cancer patients and address the urgent need for new treatment options.

Avstera Therapeutics is an oncology-focused biotech company dedicated to addressing the significant unmet needs of advanced cancer patients who have limited or no treatment options. They leverage cutting-edge approaches to tackle immunological challenges in the tumor microenvironment and are developing a pipeline of innovative therapies, including a highly specific HDAC6 inhibitor, an autologous macrophage cell therapy platform, and an mRNA cancer vaccine.

Avstera Therapeutics fosters a collaborative and innovative culture driven by a passion for developing groundbreaking cancer treatments. The company values teamwork and scientific rigor, encouraging open communication and a willingness to embrace new ideas. This collaborative environment is further strengthened by partnerships with leading academic institutions, fostering a dynamic exchange of knowledge and expertise. With a focus on making a real difference in the lives of cancer patients, Avstera cultivates a culture of dedication and purpose, driving its mission to revolutionize cancer treatment.

Avstera Therapeutics is a biotechnology company focused on tackling solid tumors. The company has a focus on foundational tumor biology science and leverages cutting-edge approaches to address key immunological challenges seen in the tumor microenvironment. Avstera is committed to building a diverse and inclusive workforce, collaborating with top cancer researchers at Georgetown University and the University of Pennsylvania. The company is passionate about creating an equitable and accessible environment for all employees.